Medical technology innovator Roche has announced that its AI-enabled continuous glucose monitoring (CGM) solution has received the Conformité Européene mark, signalling a significant advancement in diabetes management. The achievement emphasises Roche’s commitment to leveraging cutting-edge technology to improve patient outcomes, as reported by GlobalData, a leading data and analytics company.
GlobalData projects that the AI market in the medical devices industry will surpass sales of $1.2 billion by 2027, growing at a compound annual growth rate of 29.1%. The market for AI platforms across the entire healthcare sector is also expected to grow to sales of $4.3 billion by 2024, up from $1.5 billion in 2019. AI is poised to become a significant driver of innovation in medical devices.
Go deeper with GlobalData
Graysen Vigneux, medical analyst at GlobalData, comments: “AI-enabled CGM solutions offer critical advantages over traditional glucose monitoring methods, including real-time data, predictive analytics and improved patient compliance. With the CE mark, Roche’s innovative solution is poised to revolutionise diabetes management and enhance patient care.”
Roche’s AI-enabled CGM solution integrates advanced AI with CGM technology, providing patients with real-time insights and predictive alerts. This helps patients with diabetes to better manage their condition, reduce complications and improve their quality of life.
Vigneux concludes: “The CE mark approval for Roche’s AI-enabled CGM solution signifies a major advancement in the field of diabetes management. By harnessing the power of AI, this innovative solution promises to set new standards for glucose monitoring, offering patients a more proactive and informed approach to managing their health.”
The regulatory milestone both emphasises the potential of integrating AI technology into diabetes management and demonstrates Roche’s commitment to advancing healthcare innovations. As this solution becomes available to patients, Roche is poised to lead the way in providing groundbreaking tools that enhance diabetes care and improve patient outcomes globally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
